Overseeing local ocular health with a watchful gaze: Consensus on managing center-involving DME in Hong Kong
Insight into CKD progression: Ophthalmalogical outcomes and eGFR in non-diabetic CKD
Revolutionizing orbital fracture repair with 3-dimensional printing: Sharing of local cases
Diabetic macular edema is a prevalent cause of vision loss among individuals in the working-age population, characterized by the disruption of the blood-retinal barrier and the accumulation of fluid and serum macromolecules in the intercellular space. As the incidence of diabetes mellitus
Orbital fractures are amongst the commonest form of facial trauma and often require orbital reconstruction for proper management.1,2 However, the operation remains challenging as the procedure not only requires surgeons to possess profound anatomical knowledge and detailed preoperative planning, but
Dr. Chong, Kam-Lung Kelvin
Associate Professor, Department of Ophthalmologyand Visual Sciences, The Chinese University of Hong Kong
Dr. Chin, Kar-Yee Joyce
Photoactivatable nanosystem combining PDT and VEGF inhibition: A potentially safe and effective intravenous wAMD therapy
Current treatments for wet age-related macular degeneration (wAMD) include the use of vascular endothelial growth factor (VEGF) inhibitors and the use of photodynamic therapy (PDT).1 Combination of these therapies may offer significant improvements in visual acuity but safety concerns remain.1,2 Researchers from the University of Hong Kong Faculty of Medicine (HKUMed) reported the development of a novel and minimally invasive approach to wAMD treatment, by intravenously administering a photoactivatable nanosystem and irradiating the diseased eyes.1
Novel micro-invasive injectable treatment for glaucoma receives FDA approval
The travoprost intracameral implant has demonstrated non-inferiority towards topical timolol ophthalmic solution in reducing intraocular pressure (IOP) of patients with open-angle glaucoma (OAG) or ocular hypertension (OHT) in 2 phase 3 randomized controlled trial, which led to its approval from the United States (US) Food and Drug Administration (FDA) in December 2023, offering an alternate treatment option for patients with OAG or OHT.
